# CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

> **NCT03929211** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Myelodysplastic Syndromes
- Progressive Disease

## Interventions

- **DRUG:** CPI-613
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT03929211
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05
- **Primary completion:** 2022-09
- **Final completion:** 2027-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative withdrawal by IRB
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929211, "CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03929211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*